David H Ilson

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    Manish A Shah
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5201-6. 2006
  2. pmc Combined modality chemoradiation in elderly oesophageal cancer patients
    S E Anderson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 96:1823-7. 2007
  3. doi request reprint Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:2820-7. 2012
  4. ncbi request reprint Oesophageal cancer: new developments in systemic therapy
    David H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10011, USA
    Cancer Treat Rev 29:525-32. 2003
  5. pmc A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
    David H Ilson
    Gastrointestinal Oncology Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 117:1409-14. 2011
  6. ncbi request reprint Cancer of the gastroesophageal junction: Current therapy options
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell University Medical College, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 7:410-23. 2006
  7. ncbi request reprint Cancer of the gastroesophageal junction: combined modality therapy
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell University Medical College, 1275 York Avenue, New York, NY 10021, USA
    Surg Oncol Clin N Am 15:803-24. 2006
  8. ncbi request reprint Irinotecan in esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Division, Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:32-6. 2003
  9. ncbi request reprint Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer
    David H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:2926-32. 2003
  10. ncbi request reprint New developments in the treatment of esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10011, USA
    Clin Adv Hematol Oncol 2:97-104. 2004

Detail Information

Publications58

  1. ncbi request reprint Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    Manish A Shah
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5201-6. 2006
    ..We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma...
  2. pmc Combined modality chemoradiation in elderly oesophageal cancer patients
    S E Anderson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 96:1823-7. 2007
    ..Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone...
  3. doi request reprint Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:2820-7. 2012
    ..Preoperative chemoradiation improves survival in esophageal and gastroesophageal junction (GEJ) cancer. We evaluated irinotecan and cisplatin as induction chemotherapy followed by concurrent chemoradiation in esophageal cancer...
  4. ncbi request reprint Oesophageal cancer: new developments in systemic therapy
    David H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10011, USA
    Cancer Treat Rev 29:525-32. 2003
    ....
  5. pmc A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
    David H Ilson
    Gastrointestinal Oncology Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 117:1409-14. 2011
    ..Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer...
  6. ncbi request reprint Cancer of the gastroesophageal junction: Current therapy options
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell University Medical College, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 7:410-23. 2006
    ..Survival is improved with postoperative chemotherapy and radiotherapy if none has been delivered preoperatively...
  7. ncbi request reprint Cancer of the gastroesophageal junction: combined modality therapy
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell University Medical College, 1275 York Avenue, New York, NY 10021, USA
    Surg Oncol Clin N Am 15:803-24. 2006
    ..This article focuses on recent advances in the use of combined modality therapy in adenocarcinoma of the esophagus and gastroesophageal junction...
  8. ncbi request reprint Irinotecan in esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Division, Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:32-6. 2003
    ..Alternative combinations of irinotecan with radiotherapy, including the addition of docetaxel and continuous infusion 5-FU, are also undergoing phase I and II evaluation...
  9. ncbi request reprint Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer
    David H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:2926-32. 2003
    ..To identify the maximum-tolerated dose and dose-limiting toxicity (DLT) of weekly irinotecan combined with cisplatin and radiation in esophageal cancer...
  10. ncbi request reprint New developments in the treatment of esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10011, USA
    Clin Adv Hematol Oncol 2:97-104. 2004
    ....
  11. ncbi request reprint Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
    D H Ilson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 18:898-902. 2007
    ..The purpose of the study was to evaluate the efficacy of weekly paclitaxel (Taxol) in advanced esophageal cancer...
  12. ncbi request reprint Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus
    D H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:1826-34. 1998
    ..The antitumor response, toxicity, and survival of patients treated with the three-drug regimen were evaluated...
  13. ncbi request reprint Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer
    D H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 17:3270-5. 1999
    ..To evaluate the response, toxicity, survival, and quality of life in patients with unresectable or metastatic esophageal cancer treated with weekly irinotecan and cisplatin...
  14. ncbi request reprint New developments in the treatment of esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10011, USA
    Curr Oncol Rep 4:213-21. 2002
    ....
  15. ncbi request reprint Adjuvant therapy for noncolorectal cancers
    D H Ilson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 13:287-90. 2001
    ..In the adjuvant treatment of pancreatic cancer, clinical trials continue to evaluate the role of fluorouracil and radiotherapy, the use of preoperative chemoradiotherapy, and the incorporation of new therapeutic agents...
  16. doi request reprint Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Invest 27:402-6. 2009
    ..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
  17. ncbi request reprint Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
    Geoffrey Y Ku
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 62:875-80. 2008
    ..We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer...
  18. pmc Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
    Manish A Shah
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
    J Clin Oncol 29:868-74. 2011
    ..To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with advanced gastroesophageal malignancies...
  19. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  20. ncbi request reprint Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus
    Nabil P Rizk
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 883, New York, NY 10021, USA
    J Thorac Oncol 2:1117-23. 2007
    ..In this study, we evaluated prognostic factors among patients with squamous cell carcinoma (SCC) of the esophagus who have undergone a similar treatment regimen...
  21. ncbi request reprint American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma
    Nabil P Rizk
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:507-12. 2007
    ..However, none of these methods has been formally evaluated. The purpose of this study was to establish prognostic pathologic variables after CRT...
  22. ncbi request reprint Combined modality therapy in esophageal cancer: the Memorial experience
    Sibyl E Anderson
    Department of Medicine, Gastrointestinal Oncology Service Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Cornell University Weill Medical College, New York, New York 10021, USA
    Semin Surg Oncol 21:228-32. 2003
    ..The incorporation of these non-5-FU-based therapies with novel biologic agents is planned...
  23. ncbi request reprint Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 4:432-4. 2009
    ..Such a staged approach may reduce the morbidity of upfront radiation. The use of an interim positron emission tomography scan may also identify early treatment failure...
  24. ncbi request reprint Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy
    Baruch Brenner
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:45-52. 2004
    ..To define the maximum-tolerated dose (MTD) of paclitaxel when given as a weekly 96-hour infusion with cisplatin and radiotherapy for patients with esophageal cancer...
  25. doi request reprint Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer
    Inderpal S Sarkaria
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg 249:764-7. 2009
    ..We wanted to determine if endoscopic biopsy can accurately establish evidence of local pathologic complete response (pCR) in patients undergoing CRT...
  26. doi request reprint Role of neoadjuvant therapy for esophageal adenocarcinoma
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Surg Oncol Clin N Am 18:533-46. 2009
    ..Future directions include the investigation of newer chemotherapy regimens, the addition of targeted therapies, and the use of position emission tomography to provide an early assessment of response...
  27. ncbi request reprint A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results
    Manjit S Bains
    Thoracic Services, Department of Surgery, The Gastrointestinal Oncology Service, The Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Thorac Cardiovasc Surg 124:270-7. 2002
    ..We sought to evaluate treatment response to a novel combined-modality treatment regimen for localized esophageal carcinoma...
  28. ncbi request reprint Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease
    Garrett M Nash
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:954-60. 2002
    ..We have reviewed stage IV rectal cancer patients to evaluate the effectiveness of radical surgery without radiation as local therapy...
  29. doi request reprint Chemotherapeutic options for gastroesophageal junction tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Radiat Oncol 23:24-30. 2013
    ..Preoperative chemoradiation in esophageal and gastroesophageal junction tumors has also been shown to improve outcomes...
  30. doi request reprint A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
    Manish A Shah
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 29:1475-81. 2011
    ..We examined the single agent efficacy of bortezomib, a selective proteasome inhibitor, in gastric adenocarcinoma...
  31. ncbi request reprint Irinotecan, cisplatin, and radiation in esophageal cancer
    David H Ilson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:11-5. 2002
    ..Full doses of weekly irinotecan (65 mg/ m2) and cisplatin (30 mg/m2) can be combined safely with concurrent radiotherapy in patients with locally advanced esophageal cancer...
  32. ncbi request reprint Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer
    David H Ilson
    Gastrointestinal Oncology Division, Solid Tumor Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:22-5. 2004
    ..A phase II trial combining this schedule of weekly cisplatin and irinotecan and concurrent radiotherapy given as preoperative therapy will also be conducted by the CALGB as a pilot trial...
  33. ncbi request reprint Esophageal cancer: adjuvant therapy
    Geoffrey Y Ku
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell University Medical College, New York, NY 10021, USA
    Cancer J 13:162-7. 2007
    ..Ongoing research involves evaluating regimens with newer chemotherapeutic drugs, such as paclitaxel or irinotecan, as well as the incorporation of targeted molecular therapies...
  34. doi request reprint Adjuvant (postoperative) therapy for esophageal cancer
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Thorac Surg Clin 23:525-33. 2013
    ..On the other hand, all proven strategies for resectable SCCs involve preoperative treatment, and there are no validated strategies for the postoperative treatment of SCC. ..
  35. ncbi request reprint Preoperative therapy in esophageal cancer
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Adv Hematol Oncol 6:371-9. 2008
    ..Targeted agents, including monoclonal antibodies that target the epidermal and vascular endothelial growth factor receptors, are in active development in phase II and III trials...
  36. ncbi request reprint Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer
    Sibyl E Anderson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, New York, USA
    Cancer Invest 21:512-6. 2003
    ..Given the activity of paclitaxel in esophageal cancer, a phase II trial of 96-hour infusion paclitaxel in esophageal cancer was undertaken...
  37. ncbi request reprint Adjuvant postoperative therapy of gastrointestinal malignancies
    D H Ilson
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
    Oncology (Williston Park) 8:75-83; discussion 83, 88-90, 95. 1994
    ..For Dukes' B2 and C rectal cancer, standard therapy is postoperative treatment with fluorouracil-based chemotherapy and concurrent pelvic radiotherapy...
  38. ncbi request reprint Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients
    Michael R Folkert
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    Brachytherapy 12:463-70. 2013
    ..In this study, we examined the outcomes and toxicities in a set of patients with superficial primary and recurrent EC treated with a consistent HDR technique...
  39. ncbi request reprint Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers
    Do Joong Park
    Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 21:1130-7. 2014
    ..Circulating factors in patients with gastric/gastroesophageal junction (GEJ) cancers may promote tumor progression and metastasis and may be targeted for therapy...
  40. doi request reprint Esophagogastric cancer: targeted agents
    Geoffrey Y Ku
    Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Treat Rev 36:235-48. 2010
    ..In this review article, we briefly discuss pre-clinical data and the rationale for targeting these pathways and summarize the results of clinical trials to-date, including completed and ongoing phase III evaluations...
  41. ncbi request reprint Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction
    Geoffrey Y Ku
    Immune Monitoring Core Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Expert Rev Anticancer Ther 8:1953-64. 2008
    ..Future directions include the investigation of novel chemotherapy regimens, the addition of targeted therapies and the use of PET to provide an early assessment of response...
  42. doi request reprint Preoperative therapy for esophageal cancer
    Geoffrey Y Ku
    Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gastroenterol Clin North Am 38:135-52, ix. 2009
    ..Adjuvant chemoradiotherapy may be considered for patients who undergo primary resection of lower esophageal/gastroesophageal junction adenocarcinoma...
  43. ncbi request reprint Cisplatin and irinotecan in upper gastrointestinal malignancies
    E M O'Reilly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncology (Williston Park) 15:42-5. 2001
    ..Preliminary data on all of these combinations suggest promising activity in upper gastrointestinal malignancies...
  44. doi request reprint Emerging tyrosine kinase inhibitors for esophageal cancer
    Geoffrey Y Ku
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Gastrointestinal Oncology Service, 300 East 66th Street, New York, NY 10065, USA
    Expert Opin Emerg Drugs 18:219-30. 2013
    ..Because of the poor prognosis for patients with esophagogastric cancers (EGCs), increasing attention has focused on targeted agents...
  45. ncbi request reprint Targeted therapies for esophageal cancer
    William P Tew
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Oncologist 10:590-601. 2005
    ..This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma...
  46. ncbi request reprint Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience
    G Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Oncol 19:533-7. 2008
    ..Esophageal small-cell carcinoma (SCC) is rare, highly malignant and the optimal treatment approach has not been defined...
  47. ncbi request reprint Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer
    A T Culliford
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 8:787-95. 2001
    ..We reviewed our institutional experience to assess patient selection, complications, and outcome...
  48. ncbi request reprint Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?
    David H Ilson
    J Clin Oncol 20:1962-4. 2002
  49. ncbi request reprint Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?
    David H Ilson
    J Clin Oncol 25:3188-90. 2007
  50. ncbi request reprint Gastric Cancer Clinical Practice Guidelines
    Jaffer Ajani
    J Natl Compr Canc Netw 4:350-66. 2006
  51. ncbi request reprint Editorial on a phase I study on combined modality therapy in esophageal cancer
    David H Ilson
    Cancer Invest 22:813-4. 2004
  52. ncbi request reprint Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword?
    David H Ilson
    J Clin Oncol 25:1155-6. 2007
  53. ncbi request reprint Targeted agents and esophageal cancer--the next step?
    Mebea Aklilu
    Wake Forest University, Winston Salem, NC 27157, USA
    Semin Radiat Oncol 17:62-9. 2007
    ..Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients who will most likely benefit...
  54. ncbi request reprint Esophageal Cancer Clinical Practice Guidelines
    Jaffer Ajani
    J Natl Compr Canc Netw 4:328-47. 2006
  55. ncbi request reprint Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan
    Geoffrey Y Ku
    J Clin Oncol 25:e14-6. 2007
  56. ncbi request reprint Treatment of localized esophageal cancer
    Baruch Brenner
    Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
    Semin Oncol 31:554-65. 2004
    ..This review will examine the available data on the current treatment approaches in LEC...
  57. ncbi request reprint Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome
    Richard D Carvajal
    Leuk Lymphoma 48:192-4. 2007
  58. ncbi request reprint PET-guided induction chemotherapy
    Robert J Downey
    Lancet Oncol 8:754-5. 2007